Compare · DERM vs SLGL

DERM vs SLGL

Side-by-side comparison of Journey Medical Corporation (DERM) and Sol-Gel Technologies Ltd. (SLGL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DERM and SLGL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • SLGL is the larger of the two at $184.2M, about 1.5x DERM ($123.9M).
  • DERM has been more active in the news (4 items in the past 4 weeks vs 3 for SLGL).
  • SLGL has more recent analyst coverage (9 ratings vs 7 for DERM).
MetricDERMSLGL
Company
Journey Medical Corporation
Sol-Gel Technologies Ltd.
Price
-
-
Market cap
$123.9M
$184.2M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2021
2018
News (4w)
4
3
Recent ratings
7
9
DERM

Journey Medical Corporation

Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

SLGL

Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo. The company was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Latest DERM

Latest SLGL